Literature DB >> 18685131

Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms.

T Schmitz-Hübsch1, M Coudert, P Bauer, P Giunti, C Globas, L Baliko, A Filla, C Mariotti, M Rakowicz, P Charles, P Ribai, S Szymanski, J Infante, B P C van de Warrenburg, A Dürr, D Timmann, S Boesch, R Fancellu, R Rola, C Depondt, L Schöls, E Zdienicka, J-S Kang, S Döhlinger, B Kremer, D A Stephenson, B Melegh, M Pandolfo, S di Donato, S Tezenas du Montcel, T Klockgether.   

Abstract

OBJECTIVE: To identify factors that determine disease severity and clinical phenotype of the most common spinocerebellar ataxias (SCAs), we studied 526 patients with SCA1, SCA2, SCA3. or SCA6.
METHODS: To measure the severity of ataxia we used the Scale for the Assessment and Rating of Ataxia (SARA). In addition, nonataxia symptoms were assessed with the Inventory of Non-Ataxia Symptoms (INAS). The INAS count denotes the number of nonataxia symptoms in each patient.
RESULTS: An analysis of covariance with SARA score as dependent variable and repeat lengths of the expanded and normal allele, age at onset, and disease duration as independent variables led to multivariate models that explained 60.4% of the SARA score variance in SCA1, 45.4% in SCA2, 46.8% in SCA3, and 33.7% in SCA6. In SCA1, SCA2, and SCA3, SARA was mainly determined by repeat length of the expanded allele, age at onset, and disease duration. The only factors determining the SARA score in SCA6 were age at onset and disease duration. The INAS count was 5.0 +/- 2.3 in SCA1, 4.6 +/- 2.2 in SCA2, 5.2 +/- 2.5 in SCA3, and 2.0 +/- 1.7 in SCA6. In SCA1, SCA2, and SCA3, SARA score and disease duration were the strongest predictors of the INAS count. In SCA6, only age at onset and disease duration had an effect on the INAS count.
CONCLUSIONS: Our study suggests that spinocerebellar ataxia (SCA) 1, SCA2, and SCA3 share a number of common biologic properties, whereas SCA6 is distinct in that its phenotype is more determined by age than by disease-related factors.

Entities:  

Mesh:

Year:  2008        PMID: 18685131     DOI: 10.1212/01.wnl.0000325057.33666.72

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  84 in total

1.  The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study.

Authors:  H Jacobi; P Bauer; P Giunti; R Labrum; M G Sweeney; P Charles; A Dürr; C Marelli; C Globas; C Linnemann; L Schöls; M Rakowicz; R Rola; E Zdzienicka; T Schmitz-Hübsch; R Fancellu; C Mariotti; C Tomasello; L Baliko; B Melegh; A Filla; C Rinaldi; B P van de Warrenburg; C C P Verstappen; S Szymanski; J Berciano; J Infante; D Timmann; S Boesch; S Hering; C Depondt; M Pandolfo; J-S Kang; S Ratzka; J Schulz; S Tezenas du Montcel; T Klockgether
Journal:  Neurology       Date:  2011-08-10       Impact factor: 9.910

Review 2.  Inherited neuropathies: clinical overview and update.

Authors:  Christopher J Klein; Xiaohui Duan; Michael E Shy
Journal:  Muscle Nerve       Date:  2013-06-26       Impact factor: 3.217

Review 3.  Neurological diseases and pain.

Authors:  David Borsook
Journal:  Brain       Date:  2011-11-08       Impact factor: 13.501

4.  Clinical and molecular effect on offspring of a marriage of consanguineous spinocerebellar ataxia type 7 mutation carriers: a family case report.

Authors:  Jonathan J Magaña; Yessica S Tapia-Guerrero; Luis Velázquez-Pérez; Tania Cruz-Mariño; Cesar M Cerecedo-Zapata; Rocío Gómez; Nadia M Murillo-Melo; Rigoberto González-Piña; Oscar Hernández-Hernández; Bulmaro Cisneros
Journal:  Int J Clin Exp Med       Date:  2014-12-15

5.  Dystonia and ataxia progression in spinocerebellar ataxias.

Authors:  Pei-Hsin Kuo; Shi-Rui Gan; Jie Wang; Raymond Y Lo; Karla P Figueroa; Darya Tomishon; Stefan M Pulst; Susan Perlman; George Wilmot; Christopher M Gomez; Jeremy D Schmahmann; Henry Paulson; Vikram G Shakkottai; Sarah H Ying; Theresa Zesiewicz; Khalaf Bushara; Michael D Geschwind; Guangbin Xia; S H Subramony; Tetsuo Ashizawa; Sheng-Han Kuo
Journal:  Parkinsonism Relat Disord       Date:  2017-10-23       Impact factor: 4.891

6.  Long-term evolution of patient-reported outcome measures in spinocerebellar ataxias.

Authors:  Heike Jacobi; Sophie Tezenas du Montcel; Peter Bauer; Paola Giunti; Arron Cook; Robyn Labrum; Michael H Parkinson; Alexandra Durr; Alexis Brice; Perrine Charles; Cecilia Marelli; Caterina Mariotti; Lorenzo Nanetti; Lidia Sarro; Maria Rakowicz; Anna Sulek; Anna Sobanska; Tanja Schmitz-Hübsch; Ludger Schöls; Holger Hengel; Laszlo Baliko; Bela Melegh; Alessandro Filla; Antonella Antenora; Jon Infante; José Berciano; Bart P van de Warrenburg; Dagmar Timmann; Sandra Szymanski; Sylvia Boesch; Wolfgang Nachbauer; Jun-Suk Kang; Massimo Pandolfo; Jörg B Schulz; Audrey Tanguy Melac; Alhassane Diallo; Thomas Klockgether
Journal:  J Neurol       Date:  2018-06-29       Impact factor: 4.849

7.  Inventory of Non-Ataxia Signs (INAS): validation of a new clinical assessment instrument.

Authors:  H Jacobi; M Rakowicz; R Rola; R Fancellu; C Mariotti; P Charles; A Dürr; M Küper; D Timmann; C Linnemann; L Schöls; O Kaut; C Schaub; A Filla; L Baliko; B Melegh; J-S Kang; P Giunti; B P C van de Warrenburg; R Fimmers; T Klockgether
Journal:  Cerebellum       Date:  2013-06       Impact factor: 3.847

8.  Writer's cramp in spinocerebellar ataxia Type 1.

Authors:  Geeta Anjum Khwaja; Abhilekh Srivastava; Vijay Vishwanath Ghuge; Neera Chaudhry
Journal:  J Neurosci Rural Pract       Date:  2016 Oct-Dec

9.  Recessive spinocerebellar ataxia with paroxysmal cough attacks: a report of five cases.

Authors:  Luis Velázquez-Pérez; Rigoberto González-Piña; Roberto Rodríguez-Labrada; Raul Aguilera-Rodríguez; Lourdes Galicia-Polo; Yaimeé Vázquez-Mojena; Ana M Cortés-Rubio; Marla R Trujillo-Bracamontes; Cesar M Cerecedo-Zapata; Oscar Hernández-Hernández; Bulmaro Cisneros; Jonathan J Magaña
Journal:  Cerebellum       Date:  2014-04       Impact factor: 3.847

10.  Effects of Physical Rehabilitation in Patients with Spinocerebellar Ataxia Type 7.

Authors:  Karla Tercero-Pérez; Hernán Cortés; Yessica Torres-Ramos; Roberto Rodríguez-Labrada; César M Cerecedo-Zapata; Oscar Hernández-Hernández; Nelson Pérez-González; Rigoberto González-Piña; Norberto Leyva-García; Bulmaro Cisneros; Luis Velázquez-Pérez; Jonathan J Magaña
Journal:  Cerebellum       Date:  2019-06       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.